Hikma is offering micafungin for injection in dosage strengths of 50 mg and 100 mg.
The medication is indicated for the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients aged 4 months of age and older; treatment of Esophageal Candidiasis in adult and pediatric patients aged 4 months of age and older; and prophylaxis of Candida Infections in adult and pediatric aged patients 4 months of age and older undergoing hematopoietic stem cell transplantation.
[Read more: Hikma intros Kloxxado]
Micafungin for injection had a market value of $132 million in the 12 months ended August 2021, according to IQVIA.
[Read more: Hikma to acquire Custopharm]